Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment

27 May 2025

Abstract excerpt

Ovarian cancer remains a leading cause of cancer-related deaths due to late-stage diagnosis and treatment resistance. While surgery and chemotherapy are standard treatments, challenges such as platinum resistance, tumor heterogeneity, and limited therapeutic options persist. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic strategy for treating ovarian cancer (OC), particularly in cases of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial and Cervical Cancer Treatments
Share to HER2/EGFR in Cancer Research
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40514426
DOI: 10.1038/s41388-025-03448-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentPMID 40514426Read ↗

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity Read ↗

Spatial, Temporal, and Molecular Heterogeneity of ADC targets in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian CancersSemantic proximity Read ↗

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.Semantic proximity Read ↗

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment OptionsSemantic proximity Read ↗

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read ↗

Multi-Omic Profiling Reveals Antibody-Drug Conjugate Targetability in Ovarian CancerSemantic proximity Read ↗

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read ↗

From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug DiscoverySemantic proximity Read ↗

From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug DiscoverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.